Toceranib, whose commercial name is Palladia, is an important veterinary anti-cancer drug.
The following is a detailed introduction about Toceranib:
1. Basic Information
· Chemical Name: (Z)-N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indole-3-substituted)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
· CAS Number: 145918-28-1
· Molecular Formula: C₂₃H₂₉FN₄O₂
· Molecular Weight: 428.50 g/mol
· Trade Name: Palladia (Parladiya)
2. Mechanism of Action and Pharmacology
Toceranib is a receptor tyrosine kinase inhibitor.
· Target: It mainly functions by inhibiting a group of proteins known as "lysis kinase receptors". The most important targets include:
· Vascular Endothelial Growth Factor Receptor (VEGFR): Inhibiting this target can prevent the formation of tumor blood vessels, thereby "starving" the tumor and cutting off its supply of nutrients and oxygen.
· Platelet-Derived Growth Factor Receptor (PDGFR)
· Stem Cell Factor Receptor (KIT): This target is crucial for the treatment of canine mast cell tumors, as many of these tumors have mutations in the KIT gene and are continuously activated.
· Fms-like Tyrosine Kinase-3 (FLT-3)
By inhibiting these key signaling pathways, Toceranib can inhibit the proliferation of tumor cells, promote their apoptosis (programmed cell death), and suppress the formation of tumor blood vessels.
3. Main Uses
Toceranib is mainly used for cancer treatment in dogs.
· Main indications:
· Resectable canine mast cell tumors with high metastasis risk: This is its primary and most common application. After surgical removal of the tumor, Toceranib can eliminate small residual lesions, reducing the risk of recurrence and metastasis.
· Inoperable (including metastatic) canine mast cell tumors: For tumors that cannot be completely removed through surgery, Toceranib can be used as palliative treatment to control tumor growth, prolong the life of the affected dog, and improve its quality of life.
· Other possible tumor types (to be used under the guidance of veterinary oncologists):
· Angiosarcoma
· Other some solid tumors
Important Note: This medication has not been approved for use in humans or other animal species (such as cats). Its use in cats is considered "off-label use" and requires extreme caution. It must be evaluated by an experienced veterinarian.
4. Administration and Dosage
· Formulation: Oral tablets, available in various strengths such as 10mg, 15mg and 50mg.
· Administration schedule: Usually an intermittent administration schedule is adopted, such as administration every other day or three times a week (e.g. Monday, Wednesday, Friday). This schedule helps to maintain the therapeutic effect while managing potential side effects.
· Individualized treatment: The dosage needs to be precisely calculated by the veterinarian based on the dog's weight, body surface area, tumor type and overall health condition. Close monitoring is required during the treatment period.
5. Common Side Effects
Like most chemotherapy drugs, Toceranib may also cause side effects, but their severity is usually milder than that of traditional chemotherapy drugs. Common side effects include:
· Gastrointestinal reactions: The most common ones include loss of appetite, vomiting, and diarrhea.
· Bone marrow suppression: May lead to a decrease in neutrophils and platelets, increasing the risk of infection and bleeding.
· Fatigue/Drowsiness
· Weight loss
· Pancreatitis (a relatively serious but rare side effect)
These side effects are usually manageable. The veterinarian will manage them by adjusting the dosage, suspending the administration, or using supportive medications (such as anti-nausea drugs and gastrointestinal protectants).
6. Research and History
Toceranib is structurally and mechanismally very similar to the human anti-cancer drug Sunitinib, and can be regarded as the veterinary version of Sunitinib. It was developed by the animal health division of Pfizer (now Zoetis) and was approved by the US FDA in 2009, becoming the first receptor tyrosine kinase inhibitor drug specifically developed for the treatment of canine cancers. Its launch is a milestone in the field of veterinary oncology treatment.
Summary
CAS 145918-28-1 (Toceranib, Palladia) is a veterinary molecular targeted anti-cancer drug, mainly used for treating mast cell tumors in dogs. It blocks the growth and spread of tumors by inhibiting multiple key tyrosine kinase receptors. Although it may cause side effects, it plays an irreplaceable role in effectively controlling cancer and improving the quality of life of affected dogs. It is an indispensable and important drug in modern veterinary oncology.
